Literature DB >> 22407654

Prognosis of cerebral vein thrombosis presenting as isolated headache: early vs. late diagnosis.

Joana Gameiro1, José M Ferro, Patricia Canhão, Jan Stam, Fernando Barinagarrementeria, Arne Lindgren.   

Abstract

OBJECTIVE: To analyse the outcome of cerebral venous thrombosis (CVT) patients presenting with isolated headache, specifically to compare isolated headache patients with early vs. late CVT diagnosis.
METHOD: In the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) database we compared the outcome of patients with isolated headache and a CVT diagnosed early (≤7 days from onset) vs. late (>7 days). We retrieved 100 patients with isolated headache, 52 patients with early CVT diagnosis (early isolated headache) and 48 with late CVT diagnosis (late isolated headache).
RESULTS: Neurological worsening was more frequent within early isolated headache patients (23% vs. 8%) (p = 0.045). At the last follow-up (median 411 days), 93% patients had a complete recovery, and 4% were dead or dependent, with no significant difference between early isolated headache and late isolated headache.
CONCLUSION: The outcome of CVT patients with isolated headache diagnosed early or late was similarly favourable, but there was a higher proportion of neurological worsening in the acute phase among early isolated headache patients, who need close neurological monitoring.

Entities:  

Mesh:

Year:  2012        PMID: 22407654     DOI: 10.1177/0333102412439353

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  12 in total

1.  Diagnostic imaging in the management of patients with possible cerebral venous thrombosis: a cost-effectiveness analysis.

Authors:  Dennis M Hedderich; José M Ferro; Wolfgang G Kunz
Journal:  Neuroradiology       Date:  2019-07-10       Impact factor: 2.804

2.  [Clinical course of cerebral sinus venous thrombosis. Data from a monocentric cohort study over 15 years].

Authors:  C Geisbüsch; C Lichy; D Richter; C Herweh; W Hacke; S Nagel
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 3.  Headache and acute stroke.

Authors:  Dara G Jamieson; Natalie T Cheng; Maryna Skliut
Journal:  Curr Pain Headache Rep       Date:  2014-09

Review 4.  Pain management in neurocritical care.

Authors:  Axel Petzold; Armand Girbes
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

Review 5.  Diagnosis and treatment of cerebral venous and sinus thrombosis.

Authors:  Christian Weimar
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

6.  Misdiagnosis of Cerebral Vein Thrombosis in the Emergency Department.

Authors:  Ava L Liberman; Gino Gialdini; Ekaterina Bakradze; Abhinaba Chatterjee; Hooman Kamel; Alexander E Merkler
Journal:  Stroke       Date:  2018-04-25       Impact factor: 7.914

Review 7.  Medical and Nonstroke Neurologic Causes of Acute, Continuous Vestibular Symptoms.

Authors:  Jonathan A Edlow; David E Newman-Toker
Journal:  Neurol Clin       Date:  2015-08       Impact factor: 3.787

Review 8.  D-dimer for the exclusion of cerebral venous thrombosis: a meta-analysis of low risk patients with isolated headache.

Authors:  Imanda M E Alons; Korné Jellema; Marieke J H Wermer; Ale Algra
Journal:  BMC Neurol       Date:  2015-07-28       Impact factor: 2.474

9.  Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis.

Authors:  Hafize Nalan Gunes; Burcu Gokce Cokal; Selda Keskin Guler; Tahir Kurtulus Yoldas; Umit Yavuz Malkan; Cemile Sencer Demircan; Mehmet Ilker Yon; Zeynep Yoldas; Gursel Gunes; Ibrahim Celalettin Haznedaroglu
Journal:  J Int Med Res       Date:  2016-11-10       Impact factor: 1.671

Review 10.  New Developments in the Pathophysiology, Workup, and Diagnosis of Dural Venous Sinus Thrombosis (DVST) and a Systematic Review of Endovascular Treatments.

Authors:  Sanjay Konakondla; Clemens M Schirmer; Fengwu Li; Xiaogun Geng; Yuchuan Ding
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.